Show simple item record

dc.contributor.authorGraudins, A.
dc.contributor.authorMeek, R.
dc.contributor.authorEgerton-Warburton, Diana
dc.contributor.authorSeith, R.
dc.contributor.authorFurness, T.
dc.contributor.authorChapman, Rose
dc.date.accessioned2017-01-30T11:53:37Z
dc.date.available2017-01-30T11:53:37Z
dc.date.created2015-10-29T04:08:42Z
dc.date.issued2013
dc.identifier.citationGraudins, A. and Meek, R. and Egerton-Warburton, D. and Seith, R. and Furness, T. and Chapman, R. 2013. The PICHFORK (Pain InCHildren Fentanyl OR Ketamine) trial comparing the efficacy of intranasal ketamine and fentanyl in the relief of moderate to severe pain in children with limb injuries: Study protocol for a randomized controlled trial. Trials. 14 (1).
dc.identifier.urihttp://hdl.handle.net/20.500.11937/16052
dc.identifier.doi10.1186/1745-6215-14-208
dc.description.abstract

Background: The effectiveness of intranasal (IN) fentanyl as an analgesic for painful pediatric limb injuries in the Emergency Department (ED) has been reported previously. However, efficacy of IN ketamine in sub-dissociative doses is not well studied in the ED setting. A non-blinded pilot study undertaken by this study group suggested that IN ketamine showed similar analgesic effectiveness to that reported with IN fentanyl in similar non-blinded studies. The aim of this randomized, controlled, equivalence trial is to compare the analgesic effect of sub-dissociative dose IN ketamine with IN fentanyl for children with isolated musculoskeletal limb injuries.Methods/Design: This is a prospective, randomized, controlled, double-blind equivalence trial of children agedthree to thirteen years and less than 50 kg body weight, with isolated musculoskeletal limb injury, presenting to the ED with moderate to severe pain, defined as a verbal response of at least six to a standard 11-point scale (0 = none, 10 = worst pain imaginable). Pain score, sedation, satisfaction with analgesic intervention, and adverse effects will be assessed over a 60 minute interval for each participant. Intranasal ketamine (1 mg/kg) or fentanyl (1.5 microgram/kg) will be administered via blinded syringe and mucosal atomization device in a standardized volume at 0.03 ml/kg, with a maximum volume of 1.5 ml divided equally to both nares. Participants will also receive 10 mg/kg ibuprofen orally. The primary outcome measure will be median change in pain score from pre-administration to 30 minutes post-administration. Non-parametric Mann-Whitney U tests will be computed to compare median change in the primary outcome measure for IN ketamine and fentanyl. A sample size of 36 participants per group is needed to detect the expected 40 mm reduction in pain rating with a 95% confidence interval (CI) no greater than ± 10 mm at 30 minutes. Rescue analgesia will be given as IN fentanyl or intravenous morphine.Discussion: This is the first randomized-controlled trial comparing the efficacy of these two analgesic agents via the intranasal route. If IN ketamine is found to be equally effective to IN fentanyl for this indication, it will provide another analgesic agent that may be considered for the relief of acute pain in children in the ED.Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000795897. © 2013 Graudins et al.; licensee BioMed Central Ltd.

dc.titleThe PICHFORK (Pain InCHildren Fentanyl OR Ketamine) trial comparing the efficacy of intranasal ketamine and fentanyl in the relief of moderate to severe pain in children with limb injuries: Study protocol for a randomized controlled trial
dc.typeJournal Article
dcterms.source.volume14
dcterms.source.number1
dcterms.source.titleTrials
curtin.departmentNational Drug Research Institute (NDRI)
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record